After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

Senior health is also known as Geriatric care management or elder care management. It usually addresses the needs of people ...

A Neurology index related to diagnosis and treatment of all kinds of diseases of the central and peripheral nervous system ...

Sales were down 5% overall in the quarter as Pfizer weathered the loss of patent protection and the start of generic competition for big-selling pain drug Lyrica (pregabalin), which dragged sales ...

[1] Trazodone is an old second-generation antidepressant with strong sedative activity, widely used as a hypnotic drug in subtherapeutic antidepressant doses of 100 mg or less, although the ...

Drug addiction is a condition in which there is uncontrolled use of a substance with a harmful outcome. Drugs overstimulate the brain’s reward circuit, producing pleasure or euphoria. With repeated ...

Others are used to manage resulting symptoms like pain, depression, and muscle stiffness. There are several types of medications that can be used to treat MS, including chemotherapy drugs, ...

(CNN) – The U.S. Food and Drug Administration approved the first new type of pain medication in more than two decades, and it’s not an opioid. The drug is suzetrigine under the brand name ...

Drug-resistant infections occur when pathogens change in ways that render antimicrobial drugs ineffective. As a result, the pathogens survive and continue to spread. When infections are treatable with ...

As a result, there is no evidence from controlled studies on the efficacy of different initial doses or drug tapering. The only controlled study suggests that initial prednisone doses ≤ 10 mg is ...

but decided to retain a couple of late-stage projects including pain drug tanezumab and fibromyalgia therapy Lyrica (pregabalin). However, Cerevel has said it won’t be recruiting more than a ...